Latest news
25 items- SECHeat Biologics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - NightHawk Biosciences, Inc. (0001476963) (Filer)
- 13D/GSEC Form SC 13D/A filed by Heat Biologics Inc. (Amendment)SC 13D/A - NightHawk Biosciences, Inc. (0001476963) (Subject)
- SECHeat Biologics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - NightHawk Biosciences, Inc. (0001476963) (Filer)
- INSIDERSEC Form 4 filed by Wolf Jeffrey Alan4 - NightHawk Biosciences, Inc. (0001476963) (Issuer)
- INSIDERSEC Form 4 filed by Smith Edward B Iii4 - NightHawk Biosciences, Inc. (0001476963) (Issuer)
- INSIDERSEC Form 4 filed by Prendergast John K A4 - NightHawk Biosciences, Inc. (0001476963) (Issuer)
- INSIDERSEC Form 4 filed by Ostrander William L.4 - NightHawk Biosciences, Inc. (0001476963) (Issuer)
- INSIDERSEC Form 4 filed by Monahan John J4 - NightHawk Biosciences, Inc. (0001476963) (Issuer)
- SECSEC Form 10-Q filed by Heat Biologics Inc.10-Q - NightHawk Biosciences, Inc. (0001476963) (Filer)
- SECHeat Biologics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - NightHawk Biosciences, Inc. (0001476963) (Filer)
- SECSEC Form S-8 filed by Heat Biologics Inc.S-8 - NightHawk Biosciences, Inc. (0001476963) (Filer)
- SECHeat Biologics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - NightHawk Biosciences, Inc. (0001476963) (Filer)
- SECHeat Biologics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - NightHawk Biosciences, Inc. (0001476963) (Filer)
- SECSEC Form 10-Q filed by Heat Biologics Inc.10-Q - NightHawk Biosciences, Inc. (0001476963) (Filer)
- SECHeat Biologics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - NightHawk Biosciences, Inc. (0001476963) (Filer)
- SECSEC Form DEF 14A filed by Heat Biologics Inc.DEF 14A - NightHawk Biosciences, Inc. (0001476963) (Filer)
- SECHeat Biologics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits (Amendment)8-K/A - NightHawk Biosciences, Inc. (0001476963) (Filer)
- SECSEC Form 10-Q filed by Heat Biologics Inc.10-Q - NightHawk Biosciences, Inc. (0001476963) (Filer)
- SECHeat Biologics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - NightHawk Biosciences, Inc. (0001476963) (Filer)
- PRNightHawk Biosciences to Present at the 4th Annual Treg Directed Therapies Summit on PTX-35DURHAM, N.C., May 10, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE:NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Matthew Seavey, Ph.D., MBA, NightHawk's Vice President of Research will be presenting data on PTX-35, and serving on an expert panel discussing modes of Treg activation, at the 4th Annual Treg Directed Therapies Summit being held on May 17-19th in Boston. PTX-35 is a novel, potential first-in-class antibody immunomodulator of TNFRSF25 (death receptor 3), a receptor that is preferentially expressed by antigen-experienced T cells and can be utilized to expand regulator
- SECHeat Biologics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - NightHawk Biosciences, Inc. (0001476963) (Filer)
- PRHeat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under "NHWK" Effective at the Market Open TodayDURHAM, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. / NightHawk Biosciences (NYSE American: HTBX; NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that it has completed its name change from Heat Biologics, Inc. to NightHawk Biosciences, Inc. to better reflect the Company's evolution, including expansion of the therapeutic pipeline, vertical integration of capabilities from drug discovery to manufacturing and commercialization, as well as the Company's new biodefense capabilities. In connection with the name change, the Company's ticker will change to "NHWK," effective today, May
- NEWSHeat Biologics (nighthawk Biosciences) Announces That Its Elusys Therapeutics Subsidiary Has Executed A Contract To Deliver ANTHIM To The Canadian Government For C$7.9MHeat Biologics, Inc. (NYSE American: HTBX) (to be renamed "NightHawk Biosciences"), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced to shareholders that its Elusys Therapeutics subsidiary has finalized a contract with the Canadian government to deliver ANTHIM® (obiltoxaximab for injection), a treatment for inhalation anthrax, for use against a potential anthrax attack. ANTHIM® will be delivered to Canada's National Emergency Strategic Stockpile under a procurement contract totaling CAD $7.9 millioni. The goal of this program is to establish a Canadian supply of Anthim for use as a medical countermea
- PRHeat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM® to the Canadian GovernmentDURHAM, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed "NightHawk Biosciences"), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced to shareholders that its Elusys Therapeutics subsidiary has finalized a contract with the Canadian government to deliver ANTHIM® (obiltoxaximab for injection), a treatment for inhalation anthrax, for use against a potential anthrax attack. ANTHIM® will be delivered to Canada's National Emergency Strategic Stockpile under a procurement contract totaling CAD $7.9 millioni. The goal of this program is to establish a Canadian
- SECHeat Biologics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - HEAT BIOLOGICS, INC. (0001476963) (Filer)
HTBX FAQ
5 questionsWhat does Heat Biologics Inc. do?
Heat Biologics, Inc., a biopharmaceutical company, engages in the development of immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer; and HS-130...Where does HTBX stock trade?
Heat Biologics Inc. (HTBX) is listed on NASDAQ.What sector and industry is HTBX in?
Heat Biologics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to HTBX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare HTBX side-by-side with any of them on Quantisnow.How can I track HTBX on Quantisnow?
Quantisnow aggregates Heat Biologics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HTBX to receive live email and push alerts on every new disclosure.